Cargando…

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

BACKGROUND: After long-term androgen deprivation therapy, 25–30% prostate cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key transcription coactivator of the Hippo pathway, has been related to cancer progression. However, its role in neuroendocrine prosta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Siyuan, Prieto-Dominguez, Nestor, Yang, Shu, Connelly, Zachary M., StPierre, Samantha, Rushing, Bryce, Watkins, Andy, Shi, Lawrence, Lakey, Meredith, Baiamonte, Lyndsey Buckner, Fazili, Tajammul, Lurie, Aubrey, Corey, Eva, Shi, Runhua, Yeh, Yunshin, Yu, Xiuping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572469/ https://www.ncbi.nlm.nih.gov/pubmed/32313141 http://dx.doi.org/10.1038/s41391-020-0229-z

Ejemplares similares

Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas
por: Beeter, Maria C, et al.
Publicado: (2023)

Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression
por: Cheng, Siyuan, et al.
Publicado: (2021)

Prostate-Derived ETS Factor (PDEF) Modulates Yes Associated Protein 1 (YAP1) in Prostate Cancer Cells: A Potential Cross-Talk between PDEF and Hippo Signaling
por: Jaiswal, Praveen Kumar, et al.
Publicado: (2019)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
por: Bhoir, Siddhant, et al.
Publicado: (2023)

YAP is required for prostate development, regeneration, and prostate stem cell function
por: Xie, Hui, et al.
Publicado: (2023)

Emerging Role of YAP and the Hippo Pathway in Prostate Cancer
por: Koinis, Filippos, et al.
Publicado: (2022)

AR activates YAP/TAZ differentially in prostate cancer
por: Salem, Omar, et al.
Publicado: (2023)

The Effect of Payer Status on Survival of Patients With Prostate Cancer
por: Suh, Winston, et al.
Publicado: (2021)

ATXN3 promotes prostate cancer progression by stabilizing YAP
por: Wu, Longxiang, et al.
Publicado: (2023)

Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures
por: Kumar, Nagi, et al.
Publicado: (2012)

Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension
por: Collak, Filiz Kisaayak, et al.
Publicado: (2017)

The Correlation between YAP and RhoA Expression in Prostate and Ovarian Tumor Stroma
por: Lee, Myung-Jin, et al.
Publicado: (2022)

NEK1-Mediated Phosphorylation of YAP1 Is Key to Prostate Cancer Progression
por: Ghosh, Ishita, et al.
Publicado: (2023)

YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells
por: SHENG, XIA, et al.
Publicado: (2015)

Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition
por: Lee, Yu-Chen, et al.
Publicado: (2022)

Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway
por: Zeng, Hao, et al.
Publicado: (2016)

SHOX2 promotes prostate cancer proliferation and metastasis through disruption of the Hippo-YAP pathway
por: Yang, Wenjie, et al.
Publicado: (2023)

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer
por: Oseni, Saheed Oluwasina, et al.
Publicado: (2023)

YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth
por: Jiang, Ning, et al.
Publicado: (2017)

Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers
por: Marx, Andreas, et al.
Publicado: (2020)

MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer
por: Li, Qiji, et al.
Publicado: (2021)

Silibinin inhibits the migration, invasion and epithelial-mesenchymal transition of prostate cancer by activating the autophagic degradation of YAP
por: Dan, Weichao, et al.
Publicado: (2022)

Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo
por: Yang, Shu, et al.
Publicado: (2016)

Yap-Hippo Signaling Activates Mitochondrial Protection and Sustains Breast Cancer Viability under Hypoxic Stress
por: Shi, Chen, et al.
Publicado: (2021)

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
por: Wang, Yuan, et al.
Publicado: (2016)

Muscarinic receptors promote castration resistant growth of prostate cancer through a FAK-YAP signaling axis
por: Goto, Yusuke, et al.
Publicado: (2020)

YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer
por: Lee, Hsiu-Chi, et al.
Publicado: (2021)

Cerebral Cavernous Malformation 1 Determines YAP/TAZ Signaling-Dependent Metastatic Hallmarks of Prostate Cancer Cells
por: Park, Sangryong, et al.
Publicado: (2021)

TPM2 attenuates progression of prostate cancer by blocking PDLIM7-mediated nuclear translocation of YAP1
por: Wu, Zonglong, et al.
Publicado: (2023)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
por: Montgomery, Bruce, et al.
Publicado: (2010)

FSCN1 Promotes Glycolysis and Epithelial-Mesenchymal Transition in Prostate Cancer through a YAP/TAZ Signaling Pathway
por: Li, Minghui, et al.
Publicado: (2022)

Evidence for the Desmosomal Cadherin Desmoglein-3 in Regulating YAP and Phospho-YAP in Keratinocyte Responses to Mechanical Forces
por: Uttagomol, Jutamas, et al.
Publicado: (2019)

The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer
por: Zheng, Song, et al.
Publicado: (2019)

The influence of prostate volume on clinical parameters in prostate cancer screening
por: Shan, Jiahao, et al.
Publicado: (2022)

Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer
por: Huang, Gang, et al.
Publicado: (2022)

CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling
por: Lai, Chih-Jen, et al.
Publicado: (2019)

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
por: Iannelli, Federica, et al.
Publicado: (2020)

YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression
por: Shen, Tianyu, et al.
Publicado: (2020)

Detection of YAP1 and AR-V7 mRNA for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform
por: Broomfield, Joseph, et al.
Publicado: (2022)

Retracted: FSCN1 Promotes Glycolysis and Epithelial-Mesenchymal Transition in Prostate Cancer through a YAP/TAZ Signaling Pathway
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ou61jq7j80fru05rnaj1qu7f80